Michael Harrison, MD
Medical Oncology · Durham, NCNPI 1760674535
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $97,324 of the $161,031 with a category attached, or 60.4%. 20 manufacturers reported payments, led by Exelixis Inc. at 59.6% of the total. Reporting peaked in 2019 at $47,305 and has fallen 71.7% since, to $13,406 in 2025. Among medical oncology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $925.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$96K
- Pfizer$21K
- Eisai Inc.$13K
- Johnson & Johnson$7K
- E.r. Squibb & Sons, L.L.C.$5K
- Sanofi$4K
- plus $15K from 14 others
Across 150 payments — averaging $19,352 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.6M
- Seagen Inc.$438K
- Genentech, Inc.$211K
- Pfizer$121K
- Acerta Pharma LLC$120K
- Exelixis Inc.$113K
- plus $260K from 5 others
What the payments were for
- Consulting fees$42,59626%
- Speaking & faculty fees$97,32460%
- Travel & lodging$14,9429%
- Food & beverage$6,1574%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 91 | $96,032 |
| Pfizer | 12 | $20,702 |
| Eisai Inc. | 17 | $13,489 |
| Johnson & Johnson | 11 | $6,694 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,975 |
| Sanofi | 8 | $4,179 |
| Avyxa Pharma, LLC | 5 | $3,016 |
| AVEO Pharmaceuticals, Inc. | 6 | $2,847 |
| Immunomedics, Inc. | 1 | $2,700 |
| Telix Pharmaceuticals | 2 | $2,149 |
| Seagen Inc. | 4 | $1,822 |
| Janssen Scientific Affairs, LLC | 2 | $1,650 |
| Novartis | 4 | $222 |
| Dendreon Pharmaceuticals LLC | 1 | $123 |
| Astellas Pharma US Inc | 2 | $112 |
| Genentech USA, Inc. | 1 | $100 |
| AstraZeneca | 1 | $90 |
| Sumitomo Pharma America, Inc. | 1 | $87 |
| Astellas Pharma Global Development | 1 | $30 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$161,031 in reported general payments places this provider in the 90th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 55 | $1,264,898 |
| LenvimaLenvatinib Mesylate | 23 | $507,758 |
| NubeqaDarolutamide | 23 | $326,686 |
| XtandiEnzalutamide | 23 | $219,147 |
| OrgovyxRelugolix | 23 | $72,073 |
| Everolimus | 18 | $44,081 |
| EliquisApixaban | 23 | $18,471 |
| Bicalutamide | 24 | $320 |
| Dexamethasone | 11 | $268 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $252 |
| Prochlorperazine Maleate | 18 | $214 |
| Prednisone | 55 | $201 |
| Levothyroxine Sodium | 14 | $170 |
| Gabapentin | 12 | $139 |
| Ondansetron Hcl | 13 | $127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $96,032 | $1,264,89855 claims |
| Eisai Inc.Lenvima | $13,489 | $507,75823 claims |
| BayerNubeqa | $12 | $326,68623 claims |
| Astellas Pharma US IncXtandi | $112 | $219,14723 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $87 | $72,07323 claims |
| PfizerEliquis | $20,702 | $18,47123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 170 medical oncology providers in North Carolina.
Other medical oncology in Durham
- Thomas LeblancDurham$1.7M
- Andrew ArmstrongDurham$377K
- John StricklerDurham$319K
- Neal ReadyDurham$309K
- Jeffrey ClarkeDurham$140K
- Sundhar RamalingamDurham$93K
- Arif KamalDurham$50K
- Nelson ChaoDurham$45K
- Laura AlderDurham$34K
- Kaushik SenDurham$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.